122 related articles for article (PubMed ID: 33617910)
21. Simultaneous integrated boost irradiation after breast-conserving surgery: physician-rated toxicity and cosmetic outcome at 30 months' follow-up.
Bantema-Joppe EJ; Schilstra C; de Bock GH; Dolsma WV; Busz DM; Langendijk JA; Maduro JH
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e471-7. PubMed ID: 22494592
[TBL] [Abstract][Full Text] [Related]
22. Cost and Cost-Effectiveness of Image Guided Partial Breast Irradiation in Comparison to Hypofractionated Whole Breast Irradiation.
Shah C; Ward MC; Tendulkar RD; Cherian S; Vicini F; Singer ME
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):397-402. PubMed ID: 30253236
[TBL] [Abstract][Full Text] [Related]
23. Simultaneous
Eggert MC; Janssen S; Yu NY; Rades D
Anticancer Res; 2023 Oct; 43(10):4651-4655. PubMed ID: 37772551
[TBL] [Abstract][Full Text] [Related]
24. HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results - Interim analysis.
Chakraborty S; Chatterjee S;
Radiother Oncol; 2022 Sep; 174():59-68. PubMed ID: 35817323
[TBL] [Abstract][Full Text] [Related]
25. Comment to "Long term results of a phase II trial of hypofractionated adjuvant radiotherapy for early-stage breast cancer with volumetric modulated arc therapy and simultaneous integrated boost".
Kao YS
Radiother Oncol; 2022 Jan; 166():100. PubMed ID: 34856289
[No Abstract] [Full Text] [Related]
26. Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study.
Jorgo K; Polgar C; Major T; Stelczer G; Herein A; Pocza T; Gesztesi L; Agoston P
Pathol Oncol Res; 2020 Apr; 26(2):905-912. PubMed ID: 30888646
[TBL] [Abstract][Full Text] [Related]
27. Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis.
Tamihardja J; Schortmann M; Lawrenz I; Weick S; Bratengeier K; Flentje M; Guckenberger M; Polat B
Strahlenther Onkol; 2021 Feb; 197(2):124-132. PubMed ID: 32833036
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant breast radiotherapy using a simultaneous integrated boost: clinical and dosimetric perspectives.
Alford SL; Prassas GN; Vogelesang CR; Leggett HJ; Hamilton CS
J Med Imaging Radiat Oncol; 2013 Apr; 57(2):222-9. PubMed ID: 23551785
[TBL] [Abstract][Full Text] [Related]
29. Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial.
Krug D; Vonthein R; Schreiber A; Boicev AD; Zimmer J; Laubach R; Weidner N; Dinges S; Hipp M; Schneider R; Weinstrauch E; Martin T; Hörner-Rieber J; Olbrich D; Illen A; Heßler N; König IR; Dellas K; Dunst J
Strahlenther Onkol; 2021 Sep; 197(9):802-811. PubMed ID: 33320286
[TBL] [Abstract][Full Text] [Related]
30. Dosimetric Comparison of Sequential
Onal C; Efe E; Guler OC; Yildirim BA
In Vivo; 2019; 33(6):2181-2189. PubMed ID: 31662554
[TBL] [Abstract][Full Text] [Related]
31. A comparative analysis between sequential boost and integrated boost intensity-modulated radiation therapy with concurrent chemotherapy for locally-advanced head and neck cancer.
Vlacich G; Stavas MJ; Pendyala P; Chen SC; Shyr Y; Cmelak AJ
Radiat Oncol; 2017 Jan; 12(1):13. PubMed ID: 28086954
[TBL] [Abstract][Full Text] [Related]
32. A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma.
Lertbutsayanukul C; Prayongrat A; Kannarunimit D; Chakkabat C; Netsawang B; Kitpanit S
Strahlenther Onkol; 2018 May; 194(5):375-385. PubMed ID: 29302704
[TBL] [Abstract][Full Text] [Related]
33. Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy.
De Santis MC; Bonfantini F; Di Salvo F; Dispinzieri M; Mantero E; Soncini F; Baili P; Sant M; Bianchi G; Maggi C; Di Cosimo S; Agresti R; Pignoli E; Valdagni R; Lozza L
Breast; 2016 Oct; 29():90-5. PubMed ID: 27476083
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade gliomas.
Farzin M; Molls M; Astner S; Rondak IC; Oechsner M
Strahlenther Onkol; 2015 Dec; 191(12):945-52. PubMed ID: 26340939
[TBL] [Abstract][Full Text] [Related]
35. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
[TBL] [Abstract][Full Text] [Related]
36. A comparison of clinical outcomes between simultaneous integrated boost (SIB) versus sequential boost (SEQ) intensity modulated radiation therapy (IMRT) for head and neck cancer: A meta-analysis.
Jiang L; Zhang Y; Yang Z; Liang F; Wu J; Wang R
Medicine (Baltimore); 2019 Aug; 98(34):e16942. PubMed ID: 31441887
[TBL] [Abstract][Full Text] [Related]
37. Analysis of Outcomes Using Hypofractionated Tumor Bed Boost Combined With Hypofractionated Whole Breast Irradiation for Early-stage Breast Cancer.
Yu E; Huang D; Leonard K; Dipetrillo T; Wazer D; Hepel J
Clin Breast Cancer; 2017 Dec; 17(8):638-643. PubMed ID: 28629952
[TBL] [Abstract][Full Text] [Related]
38. Hypofractionated whole breast radiotherapy with or without hypofractionated boost in early stage breast cancer patients: a mono-institutional analysis of skin and subcutaneous toxicity.
Palumbo I; Mariucci C; Falcinelli L; Perrucci E; Lancellotta V; Podlesko AM; Marcantonini M; Saldi S; Bini V; Aristei C
Breast Cancer; 2019 May; 26(3):290-304. PubMed ID: 30341747
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous Integrated Boost Volumetric Modulated Arc Therapy in the Postoperative Treatment of High-Risk to Intermediate-Risk Endometrial Cancer: Results of ADA II Phase 1-2 Trial.
Macchia G; Cilla S; Deodato F; Ianiro A; Legge F; Marucci M; Cammelli S; Perrone AM; De Iaco P; Gambacorta MA; Autorino R; Valentini V; Morganti AG; Ferrandina G
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):606-13. PubMed ID: 27681755
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
